Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
View original at globenewswire.comAkari Therapeutics Issues 2025 End of Year Letter to Shareholders TAMPA, Fla. and LONDON, Dec…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both single agent and in combination
80% confidencePH1's 1-2 punch mechanism has been demonstrated to improve therapeutic durability, depth of response and remissions and significantly extend survival of preclinical models relative to current ADC therapies
80% confidenceSITC submission was noted as one of the top 150 submissions at the conference and garnered great enthusiasm from academic researchers and pharmaceutical scientists
80% confidenceAKTX-101 demonstrated compelling activity in both urothelial (bladder) and gastric cancer preclinical models
80% confidenceEntering Phase 1 clinical studies will be a unique inflection point that historically correlates with increased visibility, investor interest and potential strategic partnerships
80% confidenceAKTX-101 has shown significant activity and prolonged survival relative to ADCs with traditional payloads in preclinical studies
80% confidencePH1 payload was specifically designed to overcome key limitations of existing ADC payload classes by delivering potent cytotoxic activity, unique immune activation, and differentiated safety profile
80% confidence2026 will be a pivotal and transformational year for Akari Therapeutics
80% confidencePreclinical improvements are believed to translate into superior outcomes for cancer patients in future clinical trials
80% confidence2025 was a year of meaningful progress and significant achievements towards creating best-in-class ADCs to transform current cancer therapies
80% confidencePartnership with WuXi XDC signals confidence that one of the best global partners wants to work with Akari to advance its innovative ADC into clinical trials
80% confidencePartnering with WuXi XDC enables Akari to quickly advance AKTX-101 toward first-in-human trials planned for late 2026 or early 2027, subject to regulatory clearance
80% confidenceSafety profile of AKTX-101 suggests potential for improved tolerability in clinical settings compared to current Trop2 ADCs
80% confidence